{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '59', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '3. Have confirmation that EGFR-, ALK-, or ROSI-directed therapy is not indicated as', 'primary therapy (documentation of the absence of tumor-activating EGFR mutations [eg,', 'DEL19 or L858R], AND absence of ALK and ROSI gene rearrangements OR presence of', 'a Kirsten rat sarcoma [K-ras] mutation).', \"Note: If participant's tumor is known to have a predominantly squamous histology,\", 'molecular testing for EGFR mutation and ALK and ROSI translocations will not be', 'required, as this is not part of current diagnostic guidelines.', '4. Have measurable disease based on RECIST 1.1, as determined by the local site.', 'Note: Lesions that appear measurable but are situated in a previously irradiated area can', 'be considered measurable (eligible for selection as target lesions) if they have shown', 'documented growth since the completion of radiation.', '5. Tumor tissue that demonstrates PD-L1 expression in >1% of tumor cells (TPS 1%) as', 'assessed by IHC 22C3 pharmDx at a central laboratory.', 'Note: Assessment of PD-L1 expression must be made from provided archival tumor', 'tissue sample or newly obtained core or excisional biopsy of a tumor lesion not', 'previously irradiated. (A fine-needle aspirate, frozen sample, plastic-embedded sample,', 'cell block, clot, bone, bone marrow, cytologic specimen, or decalcified or formalin-fixed', 'sample that was frozen at any point will not be acceptable for analysis). Formalin-fixed,', 'paraffin-embedded tissue blocks are preferred to slides. Newly obtained biopsies are', 'preferred to archived tissue.', 'Demographics', '6. Be >18 years of age, inclusive, at the time of signing the ICF.', '7. Have a life expectancy of at least 3 months.', '8. Have an ECOG performance status of 0 or 1 within 7 days before the first dose of study', 'intervention but before randomization.', 'Contraceptive use', 'Contraceptive use by men and women should be consistent with local regulations regarding', 'the methods of contraception for those participating in clinical studies. If the contraception', 'requirements in the local label for any of the study interventions is more stringent than the', 'requirements above, the local label requirements are to be followed.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '60', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Male Participants', '9. Male participants are eligible to participate if they agree to the following during the', 'intervention period and for at least 7 days after the last dose of lenvatinib/matching', 'placebo:', 'Be abstinent from heterosexual intercourse as their preferred and usual lifestyle', '(abstinent on a long-term and persistent basis) and agree to remain abstinent', 'OR', 'Must agree to use contraception unless confirmed to be azoospermic (vasectomized', 'or secondary to medical cause [Appendix 5]) as detailed below:', '- Agree to use a male condom plus partner use of an additional contraceptive', 'method when having penile-vaginal intercourse with a woman of childbearing', 'potential (WOCBP) who is not currently pregnant.', 'Note: Men with a pregnant or breastfeeding partner must agree to remain', 'abstinent from penile-vaginal intercourse or use a male condom during each', 'episode of penile-vaginal penetration.', '-', 'Please note that 7 days after lenvatinib/matching placebo is stopped, if the', 'participant is on pembrolizumab only, no male contraception measures are', 'needed.', 'Female Participants', '10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and', 'at least one of the following conditions applies:', 'Is not a WOCBP.', 'OR', 'Is a WOCBP and using a contraceptive method that is highly effective (with a failure', 'rate of <1% per year), with low user dependency, or be abstinent from heterosexual', 'intercourse as their preferred and usual lifestyle (abstinent on a long term and', 'persistent basis), as described in Appendix 5 during the intervention period and for at', 'least 120 days post pembrolizumab or 30 days post lenvatinib/matching placebo,', 'whichever occurs last. The investigator should evaluate the potential for contraceptive', 'method failure (ie, noncompliance, recently initiated) in relationship to the first dose', 'of study intervention.', 'A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as', 'required by local regulations) within 24 hours before the first dose of study', 'intervention.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}